[
    [
        {
            "time": "2018-03-15",
            "original_text": "Gilead Sciences Slips on Goldman's Downgrade to Sell",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Slips",
                    "Goldman",
                    "Downgrade",
                    "Sell"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Gilead Sciences Slips on Goldman's Downgrade to Sell",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy",
            "features": {
                "keywords": [
                    "Goldman",
                    "Sachs",
                    "Picks",
                    "Big",
                    "Pharma",
                    "Stocks",
                    "Buy"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "J&J Stock Up This Year So Far: Will the Momentum Continue?",
            "features": {
                "keywords": [
                    "J&J",
                    "Stock",
                    "Up",
                    "Momentum",
                    "Continue"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "J&J Stock Up This Year So Far: Will the Momentum Continue?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "This 5% Dividend Yield Isn't Good Enough for Me",
            "features": {
                "keywords": [
                    "Dividend",
                    "Yield",
                    "Good",
                    "Enough"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "This 5% Dividend Yield Isn't Good Enough for Me",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]